Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease

Matthew J. Pianko, Evangelos Terpos, G. David Roodman, Chaitanya R. Divgi, Sonja Zweegman, Jens Hillengass, Suzanne Lentzsch

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Detection of lytic bone lesions is crucial in the workup for multiple myeloma and very often dictates the decision to start treatment. Conventional radiography, despite decades of use, is often insufficient for detection of bone disease in multiple myeloma. Modern imaging techniques such as MRI, PET, and CT offer superior detection of myeloma bone disease and extramedullary manifestations of plasma cell dyscrasias. Novel whole-body low-dose computed tomography (WBLDCT) protocols allow for collection of superior image detail of the skeleton at doses of radiation similar to those used for conventional planar radiography. Several studies have shown that WBLDCT has a superior detection rate for lytic bone lesions compared with whole-body X-ray (WBXR), potentially leading to restaging and changes in therapy. MRI and PET provide imaging data important for assessing disease activity and prognostication. Because of several advantages over WBXR, WBLDCT is already the standard imaging technique for use in patients with multiple myeloma in many European institutions. However, the radiographic skeletal survey or WBXR is still the initial study of choice used to screen for myeloma bone disease in many institutions. In this review, we aim to explore the changing landscape of imaging for myeloma bone disease through use of modern imaging techniques.

Original languageEnglish (US)
Pages (from-to)5888-5897
Number of pages10
JournalClinical Cancer Research
Volume20
Issue number23
DOIs
StatePublished - Dec 1 2014

Fingerprint

Bone Diseases
Multiple Myeloma
Tomography
X-Rays
Radiography
Bone and Bones
Paraproteinemias
Skeleton
Radiation
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. / Pianko, Matthew J.; Terpos, Evangelos; Roodman, G. David; Divgi, Chaitanya R.; Zweegman, Sonja; Hillengass, Jens; Lentzsch, Suzanne.

In: Clinical Cancer Research, Vol. 20, No. 23, 01.12.2014, p. 5888-5897.

Research output: Contribution to journalArticle

Pianko, Matthew J. ; Terpos, Evangelos ; Roodman, G. David ; Divgi, Chaitanya R. ; Zweegman, Sonja ; Hillengass, Jens ; Lentzsch, Suzanne. / Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 23. pp. 5888-5897.
@article{5ead5181591f411ba81f23901753ce5b,
title = "Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease",
abstract = "Detection of lytic bone lesions is crucial in the workup for multiple myeloma and very often dictates the decision to start treatment. Conventional radiography, despite decades of use, is often insufficient for detection of bone disease in multiple myeloma. Modern imaging techniques such as MRI, PET, and CT offer superior detection of myeloma bone disease and extramedullary manifestations of plasma cell dyscrasias. Novel whole-body low-dose computed tomography (WBLDCT) protocols allow for collection of superior image detail of the skeleton at doses of radiation similar to those used for conventional planar radiography. Several studies have shown that WBLDCT has a superior detection rate for lytic bone lesions compared with whole-body X-ray (WBXR), potentially leading to restaging and changes in therapy. MRI and PET provide imaging data important for assessing disease activity and prognostication. Because of several advantages over WBXR, WBLDCT is already the standard imaging technique for use in patients with multiple myeloma in many European institutions. However, the radiographic skeletal survey or WBXR is still the initial study of choice used to screen for myeloma bone disease in many institutions. In this review, we aim to explore the changing landscape of imaging for myeloma bone disease through use of modern imaging techniques.",
author = "Pianko, {Matthew J.} and Evangelos Terpos and Roodman, {G. David} and Divgi, {Chaitanya R.} and Sonja Zweegman and Jens Hillengass and Suzanne Lentzsch",
year = "2014",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-14-1692",
language = "English (US)",
volume = "20",
pages = "5888--5897",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease

AU - Pianko, Matthew J.

AU - Terpos, Evangelos

AU - Roodman, G. David

AU - Divgi, Chaitanya R.

AU - Zweegman, Sonja

AU - Hillengass, Jens

AU - Lentzsch, Suzanne

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Detection of lytic bone lesions is crucial in the workup for multiple myeloma and very often dictates the decision to start treatment. Conventional radiography, despite decades of use, is often insufficient for detection of bone disease in multiple myeloma. Modern imaging techniques such as MRI, PET, and CT offer superior detection of myeloma bone disease and extramedullary manifestations of plasma cell dyscrasias. Novel whole-body low-dose computed tomography (WBLDCT) protocols allow for collection of superior image detail of the skeleton at doses of radiation similar to those used for conventional planar radiography. Several studies have shown that WBLDCT has a superior detection rate for lytic bone lesions compared with whole-body X-ray (WBXR), potentially leading to restaging and changes in therapy. MRI and PET provide imaging data important for assessing disease activity and prognostication. Because of several advantages over WBXR, WBLDCT is already the standard imaging technique for use in patients with multiple myeloma in many European institutions. However, the radiographic skeletal survey or WBXR is still the initial study of choice used to screen for myeloma bone disease in many institutions. In this review, we aim to explore the changing landscape of imaging for myeloma bone disease through use of modern imaging techniques.

AB - Detection of lytic bone lesions is crucial in the workup for multiple myeloma and very often dictates the decision to start treatment. Conventional radiography, despite decades of use, is often insufficient for detection of bone disease in multiple myeloma. Modern imaging techniques such as MRI, PET, and CT offer superior detection of myeloma bone disease and extramedullary manifestations of plasma cell dyscrasias. Novel whole-body low-dose computed tomography (WBLDCT) protocols allow for collection of superior image detail of the skeleton at doses of radiation similar to those used for conventional planar radiography. Several studies have shown that WBLDCT has a superior detection rate for lytic bone lesions compared with whole-body X-ray (WBXR), potentially leading to restaging and changes in therapy. MRI and PET provide imaging data important for assessing disease activity and prognostication. Because of several advantages over WBXR, WBLDCT is already the standard imaging technique for use in patients with multiple myeloma in many European institutions. However, the radiographic skeletal survey or WBXR is still the initial study of choice used to screen for myeloma bone disease in many institutions. In this review, we aim to explore the changing landscape of imaging for myeloma bone disease through use of modern imaging techniques.

UR - http://www.scopus.com/inward/record.url?scp=84918589950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918589950&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-1692

DO - 10.1158/1078-0432.CCR-14-1692

M3 - Article

C2 - 25294899

AN - SCOPUS:84918589950

VL - 20

SP - 5888

EP - 5897

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -